Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Strong Ongoing Earnings Outlook for 2011


      News provided by

      Abbott

      26 Jan, 2011, 12:44 GMT

      Share this article

      Share this article


      ABBOTT PARK, Illinois, January 26, 2011 /PRNewswire/ --

          
                        - Worldwide Sales Increased 13.4 Percent -
          
                  - Fourth Quarter Ongoing EPS Growth of 10.2 Percent -
          
                - Worldwide Pharmaceutical Sales Increased 22.5 Percent -
          
               - Worldwide Vascular Products Sales Increased 13.7 Percent -
          
                     - U.S. Diagnostics Sales Increased 8.5 Percent -
      

      Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2010.

          
          -- Diluted earnings per share, excluding specified items, were $1.30,
             reflecting 10.2 percent growth. Diluted earnings per share under
             Generally Accepted Accounting Principles (GAAP) were $0.92, primarily
             reflecting costs associated with recently announced restructuring
             actions for the integration of the Solvay Pharmaceuticals acquisition
             and in process R&D related to the Reata collaboration.
          -- Worldwide sales increased 13.4 percent to nearly $10 billion, 
             including an unfavorable 0.4 percent effect of foreign exchange rates. 
             Growth in the quarter was driven by worldwide pharmaceutical sales, 
             which increased 22.5 percent, including the contribution from the 
             Solvay and Piramal acquisitions, as well as worldwide vascular 
             products sales, which increased 13.7 percent.
          -- Fourth quarter results included strong investment spending, with an
             increased level of R&D spending, as well as an adjusted gross margin
             ratio of 60.6 percent, which increased 230 basis points over the prior
             year.
          -- In response to changes in the healthcare industry, including U.S.
             Health Care Reform and the challenging regulatory environment, today
             Abbott announced a restructuring in its U.S. pharmaceutical business 
             to streamline commercial and manufacturing operations, improve
             efficiencies and reduce costs.
          -- Abbott is issuing ongoing earnings-per-share guidance for the 
             full-year 2011 that reflects double-digit growth over 2010 at the 
             midpoint of the range.
      

      "Despite a very challenging environment, 2010 was another productive year for Abbott, resulting in strong financial performance," said Miles D. White, chairman and chief executive officer, Abbott. "We also took decisive long-term strategic actions to expand our emerging markets presence and late-stage pipeline to better position Abbott for sustainable long-term growth. We anticipate delivering another year of double-digit ongoing earnings-per-share growth in 2011."

          
          The following is a summary of fourth-quarter 2010 sales.
          
          
          Quarter Ended
           12/31/10
          (dollars in
           millions)                                  % Change vs. 4Q09
                                                      -----------------
                                                           Foreign
                               Sales   Reported           Exchange      Operational
                               -----   --------           --------      -----------
          
          Total Sales           $9,968   13.4               (0.4)          13.8
          
              Total
               International
               Sales            $5,681   19.4               (0.8)          20.2
          
              Total U.S.
               Sales            $4,287    6.3                 --            6.3
          
          Worldwide
           Pharmaceutical
           Sales                $5,939   22.5  (a)          (0.9)          23.4
          
              International
               Pharmaceuticals  $3,284   29.9  (a)          (1.7)          31.6
          
              U.S.
               Pharmaceuticals  $2,655   14.4  (a)            --           14.4
          
          Worldwide
           Nutritional
           Sales                $1,433    0.0  (b)           1.3           (1.3)
          
              International
               Nutritionals       $791    7.9                2.5            5.4
          
              U.S.
               Nutritionals       $642   (8.3) (b)            --           (8.3)
          
          Worldwide
           Diagnostics
           Sales                $1,015    4.1               (0.7)           4.8
          
              International
               Diagnostics        $746    2.6               (1.0)           3.6
          
              U.S.
               Diagnostics        $269    8.5                 --            8.5
          
          Worldwide
           Vascular
           Sales                  $822   13.7               (0.3)          14.0
          
               International
                Vascular          $423   36.9               (0.8)          37.7
          
               U.S. Vascular      $399   (3.7)                --           (3.7)
          
          Other Sales             $759   (6.4)              (0.6)          (5.8)
          
          
          Note:  See "Consolidated Statement of Earnings" for more information.
          
          (a) Includes impact from the acquisitions of Solvay Pharmaceuticals
              and Piramal Healthcare Solutions, which closed in 2010.
          (b) Includes impact from a nutritional product recall announced in
              September 2010.
          
          
          
          The following is a summary of twelve months ended December 2010 sales.
          
          
          Twelve Months Ended
           12/31/10
          (dollars in millions)                % Change vs. 12M09
                                               ------------------
                                          Sales            Reported
                                          -----            --------
          
          Total Sales                     $35,167            14.3
          
              Total International
               Sales                      $19,974            20.7
          
              Total U.S. Sales            $15,193             6.8
          
          Worldwide
           Pharmaceutical Sales           $19,894            20.7  (a)
          
              International
               Pharmaceuticals            $11,150            28.3  (a)
          
              U.S. Pharmaceuticals         $8,744            12.2  (a)
          
          Worldwide Nutritional
           Sales                           $5,532             4.7  (b)
          
              International
               Nutritionals                $2,943            11.1
          
              U.S. Nutritionals            $2,589            (1.8) (b)
          
          Worldwide Diagnostics
           Sales                           $3,794             6.0
          
              International
               Diagnostics                 $2,791             5.7
          
              U.S. Diagnostics             $1,003             6.9
          
          Worldwide Vascular
           Sales                           $3,194            18.6
          
               International Vascular      $1,532            40.2
          
               U.S. Vascular               $1,662             3.9
          
          Other Sales                      $2,753             1.0
      
          
          Twelve Months Ended
           12/31/10
          (dollars in millions)                % Change vs. 12M09
                                               ------------------
                                            Foreign
                                           Exchange         Operational
                                           --------         -----------
          
          Total Sales                         1.2             13.1
          
              Total International
               Sales                          2.2             18.5
          
              Total U.S. Sales                 --              6.8
          
          Worldwide
           Pharmaceutical Sales               1.0             19.7
          
              International
               Pharmaceuticals                1.9             26.4
          
              U.S. Pharmaceuticals             --             12.2
          
          Worldwide Nutritional
           Sales                              1.8              2.9
          
              International
               Nutritionals                   3.6              7.5
          
              U.S. Nutritionals                --             (1.8)
          
          Worldwide Diagnostics
           Sales                              1.6              4.4
          
              International
               Diagnostics                    2.1              3.6
          
              U.S. Diagnostics                 --              6.9
          
          Worldwide Vascular
           Sales                              1.0             17.6
          
               International Vascular         2.5             37.7
          
               U.S. Vascular                   --              3.9
          
          Other Sales                         0.6              0.4
          
          
          
          Note:  See "Consolidated Statement of Earnings" for more information.
          
          (a) Includes impact from the acquisitions of Solvay Pharmaceuticals
              and Piramal Healthcare Solutions, which closed in 2010.
          (b) Includes impact from a nutritional product recall announced in
              September 2010.
          
          
          
          
          
          The following summarizes global sales for selected products and
          related foreign exchange impacts compared to the prior year.
          
          
          
          Quarter Ended
           12/31/10
          (dollars in
           millions)
                                                        Global Sales
                                                     % Change vs. 4Q09
                                                     -----------------
                                Global                    Foreign
                                Sales   Reported          Exchange      Operational
                                -----   --------          --------      -----------
          Pharmaceutical
           Products
          
            HUMIRA              $1,879    13.0               (2.4)       15.4
          
            TRILIPIX/TriCor       $499    19.2                 --        19.2
          
            Kaletra               $341    (9.8)              (1.8)       (8.0)
          
            Niaspan               $286    12.7                 --        12.7
          
            Lupron                $200    (7.2)              (0.1)       (7.1)
          
            Synthroid             $160     8.3                0.7         7.6
          
          Nutritional
           Products
          
            Pediatric
             Nutritionals         $742    (5.6) (a)           1.6        (7.2) (a)
          
            Adult Nutritionals    $687     9.2                0.9         8.3
          
          Medical Products
          
            Core Laboratory
             Diagnostics          $828     1.0               (0.6)        1.6
          
            Coronary Stents       $514    19.5                0.7        18.8
          
            Diabetes Care         $337     1.5               (1.5)        3.0
          
            Medical Optics        $280   (11.7) (b)           0.3       (12.0) (b)
          
            Molecular
             Diagnostics          $114    21.2               (2.1)       23.3
          
          
          
          (a) Includes impact from a nutritional product recall announced in
              September 2010.
          (b) 2009 included four months of sales due to a change in reporting
              to calendar year, as previously noted.
      
          
          The following is a summary of Abbott's fourth-quarter 2010 sales for
          selected products.
          
          
          Quarter Ended 12/31/10
          (dollars in millions)
                                             U.S.
                                             ----
                                               % Change
                                    Sales      vs. 4Q09
                                    -----      --------
          Pharmaceutical
           Products
          
            HUMIRA                   $877         13.2
          
            TRILIPIX/TriCor          $418         (0.3)
          
            Kaletra                  $111        (18.9)
          
            Niaspan                  $286         12.7
          
            Lupron                   $130         (7.8)
          
            Synthroid                $131          7.0
          
          Nutritional Products
          
            Pediatric Nutritionals   $304        (15.3) (a)
          
            Adult Nutritionals       $334          3.2
          
          Medical Products
          
            Core Laboratory
             Diagnostics             $158         (0.4)
          
            Coronary Stents          $248         (5.1)
          
            Diabetes Care            $127          1.3
          
            Medical Optics           $103          6.8
          
            Molecular Diagnostics     $55         32.1
          
          
          
          
          
          
          Quarter Ended
           12/31/10
          (dollars in
           millions)                          International
                                              -------------
                                                  % Change vs. 4Q09
                                                  -----------------
                                                    Foreign
                            Sales  Reported        Exchange         Operational
                            -----  --------        --------         -----------
          Pharmaceutical
           Products
          
            HUMIRA         $1,002    12.9            (4.5)            17.4
          
            TRILIPIX/
             TriCor           $81     n/m             n/m              n/m
          
            Kaletra          $230    (4.7)           (2.9)            (1.8)
          
            Niaspan            --      --              --               --
          
            Lupron            $70    (6.1)           (0.4)            (5.7)
          
            Synthroid         $29    14.5             4.3             10.2
          
          Nutritional
           Products
          
            Pediatric
             Nutritionals    $438     2.6             3.0             (0.4)
          
            Adult
             Nutritionals    $353    15.5             1.9             13.6
          
          Medical
           Products
          
            Core Laboratory
             Diagnostics     $670     1.3            (0.8)             2.1
          
            Coronary Stents  $266    57.4             1.7             55.7
          
            Diabetes Care    $210     1.7            (2.4)             4.1
          
            Medical Optics   $177   (19.8) (b)        0.4            (20.2) (b)
          
            Molecular
             Diagnostics      $59    12.5            (3.7)            16.2
          
          
          
          
          n/m = Not meaningful
          
          (a) Includes impact from a nutritional product recall announced in
              September 2010.
          (b) 2009 included four months of sales due to a change in reporting
              to calendar year, as previously noted.
      
          
          The following summarizes global sales for selected products and
          related foreign exchange impacts compared to the prior year.
          
          
          
          Twelve Months Ended
           12/31/10
          (dollars in
           millions)
                                                       Global Sales
                                                    % Change vs. 12M09
                                                    ------------------
                              Global                  Foreign
                              Sales  Reported         Exchange         Operational
                              -----  --------         --------         -----------
          Pharmaceutical
           Products
          
            HUMIRA            $6,548    19.3              0.3            19.0
          
            TRILIPIX/
             TriCor           $1,582    18.3               --            18.3
          
            Kaletra           $1,255    (8.1)             0.3            (8.4)
          
            Niaspan             $927     8.4               --             8.4
          
            Lupron              $748    (6.5)             1.4            (7.9)
          
            Synthroid           $555    10.6              2.0             8.6
          
          Nutritional
           Products
          
            Pediatric
             Nutritionals     $2,884     1.2  (a)         1.9            (0.7) (a)
          
            Adult
             Nutritionals     $2,613    10.0              1.7             8.3
          
          Medical
           Products
          
            Core Laboratory
             Diagnostics      $3,136     3.6              1.8             1.8
          
            Coronary Stents   $2,007    24.0              1.6            22.4
          
            Diabetes Care     $1,276     2.7              0.9             1.8
          
            Medical Optics    $1,063    19.5              0.7            18.8
          
            Molecular
             Diagnostics        $385    22.1               --            22.1
          
          
          
          
          (a) Includes impact from a nutritional product recall announced in
              September 2010.
          
          
          
          The following is a summary of Abbott's twelve months ended December
          2010 sales for selected products.
          
          
          
          Twelve Months Ended
           12/31/10
          (dollars in millions)
                                           U.S.
                                           ----
                                               % Change
                                                  vs.
                                    Sales        12M09
                                    -----       ------
          Pharmaceutical Products
          
            HUMIRA                  $2,872        14.0
          
            TRILIPIX/TriCor         $1,355         1.3
          
            Kaletra                   $363       (18.7)
          
            Niaspan                   $927         8.4
          
            Lupron                    $483       (10.6)
          
            Synthroid                 $451         8.6
          
          Nutritional Products
          
            Pediatric Nutritionals  $1,208        (7.5) (a)
          
            Adult Nutritionals      $1,345         6.0
          
          Medical Products
          
            Core Laboratory
             Diagnostics              $602        (0.5)
          
            Coronary Stents         $1,047         1.7
          
            Diabetes Care             $512         2.8
          
            Medical Optics            $407        20.7
          
            Molecular Diagnostics     $189        26.6
          
          
          
          
          
          
          Twelve Months Ended
           12/31/10
          (dollars in millions)                   International
                                                  -------------
                                                     % Change vs. 12M09
                                                     ------------------
                                                         Foreign
                                   Sales  Reported      Exchange      Operational
                                   -----  --------      --------      -----------
          Pharmaceutical Products
          
            HUMIRA                 $3,676    23.8           0.6            23.2
          
            TRILIPIX/TriCor          $227     n/m           n/m             n/m
          
            Kaletra                  $892    (3.0)          0.4            (3.4)
          
            Niaspan                    --      --            --              --
          
            Lupron                   $265     2.0           4.3            (2.3)
          
            Synthroid                $104    20.2          11.5             8.7
          
          Nutritional Products
          
            Pediatric Nutritionals $1,676     8.6           3.6             5.0
          
            Adult Nutritionals     $1,268    14.7           3.7            11.0
          
          Medical Products
          
            Core Laboratory
             Diagnostics           $2,534     4.6           2.2             2.4
          
            Coronary Stents          $960    63.1           4.5            58.6
          
            Diabetes Care            $764     2.6           1.5             1.1
          
            Medical Optics           $656    18.8           1.1            17.7
          
            Molecular Diagnostics    $196    18.0            --            18.0
          
          
          
          
          n/m = Not meaningful
          
          (a) Includes impact from a nutritional product recall announced in
              September 2010.
      

      Business Highlights

          
          - Encouraging Results Presented in Chronic Kidney Disease (CKD): New
            Phase 2b pivotal data presented at the Annual American Society of
            Nephrology (ASN) suggests bardoxolone methyl, an investigational
            treatment for CKD, reverses disease progression and improves measures
            of kidney function in patients with CKD and type 2 diabetes. In the
            study, the majority of patients treated with bardoxolone experienced a
            reduction in disease severity and an improvement in kidney function. To
            date, no treatment has been shown to reverse the progression of CKD. We
            expect bardoxolone to enter Phase 3 clinical trials in early 2011. Also
            presented data from a Phase 2 study of atrasentan, in development to
            help slow CKD progression in patients with type 2 diabetic nephropathy
            (diabetic kidney disease).
          - New Results Presented on Abbott HCV Compound: Presented positive
            results from a Phase 2 study of ABT-450/r, an investigational, oral
            protease inhibitor being developed for the treatment of hepatitis C
            (HCV) infection. Initial results suggest that ABT-450/r demonstrates
            potent antiviral activity in treatment-naïve adults with HCV genotype 1
            infection. Results show that more than 90 percent of patients on study
            drug, administered with pegylated interferon/ribavirin, achieved HCV-
            RNA levels <25 IU/mL (a measure of rapid virologic response) at four
            weeks.
          - Positive Oncology Data Presented at ASH: Presented Phase 2 data at the
            Annual Meeting of the American Society of Hematology (ASH) for
            elotuzumab, a late-stage compound in development for multiple myeloma,
            the second-most common blood cancer in the United States. Interim
            results from the Phase 2 portion of a Phase 1b/2 study, showed a high
            objective response rate (ORR) among patients with relapsed multiple
            myeloma who received elotuzumab plus lenalidomide and low-dose
            dexamethasone. We anticipate initiating Phase 3 clinical trials with
            our partner company in early 2011.
          - Announced a Collaboration to Develop New Anti-cancer Drugs: Announced a
            collaboration agreement with EpiTherapeutics to develop new anti-cancer
            drugs by making small-molecule inhibitors against selected epigenetic
            oncology targets.
          - Received CE Mark for World's First Drug Eluting Bioresorbable Vascular
            Scaffold (BVS): Announced CE Mark in Europe for the world's first drug
            eluting BVS for the treatment of coronary artery disease. Abbott's
            ABSORB(TM) BVS device restores blood flow by opening a clogged vessel
            and providing support to the vessel until it dissolves, leaving
            patients with a treated vessel free of a permanent metallic implant.
          - Announced CE Mark for XIENCE PRIME(TM) for Critical Limb Ischemia
            (CLI): Received CE Mark for XIENCE PRIME Everolimus Eluting Coronary
            Stent System for the treatment of critical limb ischemia (CLI) or
            severe claudication (pain) of the lower leg. CLI is the most advanced
            form of peripheral artery disease that can ultimately lead to limb
            amputation. With this expanded indication, XIENCE PRIME can be marketed
            to treat CLI or severe claudication in European Union countries and
            others that recognize CE Mark.
          - Introduced New Vitamin D Diagnostic Test in Europe: Introduced a new
            diagnostic test in Europe to measure levels of vitamin D in blood using
            Abbott's ARCHITECT automated instrument system. According to the
            International Osteoporosis Foundation, vitamin D deficiency is a
            worldwide health issue and the percentage of the European population
            that is vitamin D insufficient is high, with some countries exceeding
            75 percent. The ARCHITECT 25-OH Vitamin D assay is a fully automated
            immunoassay that can help laboratories manage the increasing vitamin D
            testing volumes.
      

      Abbott issues earnings-per-share outlook for 2011

      Abbott is issuing ongoing earnings-per-share guidance for the full-year 2011 of $4.54 to $4.64. The midpoint of this guidance range reflects growth of 10 percent over 2010. Abbott's 2011 outlook reflects the previously outlined incremental impact of costs associated with U.S. Healthcare Reform, as well as the impact of European austerity measures.

      Abbott forecasts specified items for the full-year 2011 of approximately $0.78 per share, primarily associated with acquisition integration and cost reduction initiatives, including restructuring actions announced today to streamline commercial and manufacturing operations in Abbott's U.S. pharmaceutical business (see Q&A 3), and in-process R&D related to the Reata collaboration. Including these specified items, projected earnings per share under Generally Accepted Accounting Principles (GAAP) would be $3.76 to $3.86 for the full-year 2011.

      Abbott declares quarterly dividend

      On Dec. 10, 2010, the board of directors of Abbott declared the company's quarterly common dividend of 44 cents per share, an increase of 10 percent over the prior year. The cash dividend is payable Feb. 15, 2011, to shareholders of record at the close of business on Jan. 14, 2011. This marks the 348th consecutive dividend paid by Abbott since 1924.

      About Abbott

      Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

      Abbott's news releases and other information are available on the company's Web site at www.abbott.com. Abbott will webcast its live fourth-quarter earnings conference call through its Investor Relations Web site at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time.

      - Private Securities Litigation Reform Act of 1995 -

      A Caution Concerning Forward-Looking Statements

      Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, in Item 1A, "Risk Factors," to our quarterly reports on Securities and Exchange Commission Form 10-Q for the quarters ended March 31, 2010 and September 30, 2010, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

          
                            Abbott Laboratories and Subsidiaries
                                 Consolidated Statement of Earnings
                          Fourth Quarter Ended December 31, 2010 and 2009
                                (in millions, except per share data)
                                            (unaudited)
          
                                                    2010    2009  % Change
                                                    ----    ----  --------
          
          Net Sales                               $9,968  $8,790      13.4
                                                  ------  ------
          
          Cost of products sold                    4,045   3,784       6.9
          Research and development                 1,058     747      41.5
          Acquired in-process research and
           development                               238     170      40.1
          Selling, general and administrative      2,797   2,225      25.7
                                                   -----   -----
          Total Operating Cost and Expenses        8,138   6,926      17.5
                                                   -----   -----
          
          Operating earnings                       1,830   1,864      (1.8)
          
          Net interest expense                       129      94      36.8
          Net foreign exchange (gain) loss           (19)      7       n/m
          Other (income) expense, net                (48)    (60)    (20.4)
                                                     ---     ---
          Earnings before taxes                    1,768   1,823      (3.0)
          Taxes on earnings                          327     284      15.1
                                                     ---     ---
          Net Earnings                            $1,441  $1,539      (6.4)
                                                  ======  ======
          
          Net Earnings Excluding Specified Items,
           as described below                     $2,025  $1,845       9.7  1)
                                                  ======  ======
          
          Diluted Earnings per Common Share        $0.92   $0.98      (6.1)
                                                   =====   =====
          
          Diluted Earnings Per Common Share,
           Excluding Specified Items,
            as described below                     $1.30   $1.18      10.2  1)
                                                   =====   =====
          
          Average Number of Common Shares
           Outstanding Plus Dilutive
               Common Stock Options and Awards     1,556   1,560
          
              
          1)    2010 Net Earnings Excluding Specified Items excludes after-tax
                charges of $346 million, or $0.23 per share, related primarily
                to the acquisitions of Solvay Pharmaceuticals and Piramal
                Healthcare Solutions, as well as other cost reduction
                initiatives, and $238 million, or $0.15 per share, relating to
                acquired in-process research and development related to the
                Reata collaboration.
          
                2009 Net Earnings Excluding Specified Items excludes after-tax
                charges of $170 million, or $0.11 per share, for acquired in-
                process research and development associated with the PanGenetics
                acquisition, $99 million, or $0.07 per share, primarily for
                acquisition integration and cost reduction initiatives, and $37
                million, or $0.02 per share, primarily related to inventory write-
                offs associated with the suspension of sibutramine in certain
                countries following the European regulatory recommendation.
          
          NOTE: See attached questions and answers section for further
                explanation of Consolidated Statement of Earnings line items.
          
          n/m = Percent change is not meaningful.
          
          
          
                                Abbott Laboratories and Subsidiaries
                                 Consolidated Statement of Earnings
                           Twelve Months Ended December 31, 2010 and 2009
                                (in millions, except per share data)
                                            (unaudited)
          
                                                     2010     2009 % Change
                                                     ----     ---- --------
          
          Net Sales                               $35,167  $30,765     14.3
                                                  -------  -------
          
          Cost of products sold                    14,665   13,209     11.0
          Research and development                  3,725    2,744     35.7
          Acquired in-process research and
           development                                313      170     84.2
          Selling, general and administrative      10,376    8,406     23.4
                                                   ------    -----
          Total Operating Cost and Expenses        29,079   24,529     18.6
                                                   ------   ------
          
          Operating earnings                        6,088    6,236     (2.4)
          
          Net interest expense                        448      382     17.2
          Net foreign exchange (gain) loss            (11)      35      n/m
          Other (income) expense, net                 (62) (1,375)      n/m  1)
                                                      ---   ------
          Earnings before taxes                     5,713    7,194    (20.6)
          Taxes on earnings                         1,087    1,448    (25.0)
                                                    -----    -----
          Net Earnings                             $4,626   $5,746    (19.5)
                                                   ======   ======
          
          Net Earnings Excluding Specified Items,
           as described below                      $6,501   $5,805     12.0  2)
                                                   ======   ======
          
          Diluted Earnings per Common Share         $2.96    $3.69    (19.8) 3)
                                                    =====    =====
          
          Diluted Earnings Per Common Share,
           Excluding Specified Items,
            as described below                      $4.17    $3.72     12.1  2)
                                                    =====    =====
          
          Average Number of Common Shares
           Outstanding Plus Dilutive
               Common Stock Options and Awards      1,556    1,555
          
           
          
          1)      Other (income) expense, net, in 2009 includes the
                  derecognition of a contingent liability and a favorable
                  patent litigation settlement. These items have been treated
                  as specified items and excluded from ongoing operations.
                  2010 and 2009 also include ongoing contractual payments
                  from Takeda associated with the conclusion of the TAP joint
                  venture.
          
          2)      2010 Net Earnings Excluding Specified Items excludes after-
                  tax charges of $1.035 billion, or $0.67 per share,
                  associated primarily with the acquisitions of Solvay
                  Pharmaceuticals and Piramal Healthcare Solutions, including
                  announced restructuring plans, as well as other cost
                  reduction initiatives, $313 million, or $0.20 per share,
                  relating to acquired in-process research and development
                  related to the Reata and the Neurocrine collaborations,
                  $115 million, or $0.07 per share, for the one-time impact
                  of the devaluation of the Venezuelan bolivar on balance
                  sheet translation, $106 million, or $0.07 per share, for a
                  litigation reserve, $60 million, or $0.04 per share, for
                  specific health care reform impact on deferred tax assets,
                  $88 million, or $0.06 per share, for costs of a nutritional
                  product recall and the withdrawal of sibutramine, and $158
                  million, or $0.10 per share, for impairment of the
                  intangible asset related to sibutramine.
          
                  2009 Net Earnings Excluding Specified Items excludes an
                  after-tax gain of $505 million, or $0.32 per share,
                  relating to the derecognition of a contingent liability and
                  an after-tax gain of $182 million, or $0.12 per share,
                  relating to a patent litigation settlement. This was offset
                  by $170 million, or $0.11 per share, for acquired in-
                  process research and development, $164 million, or $0.10
                  per share, primarily relating to costs associated with the
                  acquisition of Advanced Medical Optics, $68 million, or
                  $0.04 per share, for litigation settlements and $344
                  million, or $0.22 per share, primarily for cost reduction
                  initiatives and costs associated with a delayed product
                  launch.
          
          3)      Effective January 1, 2009, Abbott adopted FSP EITF 03-6-1,
                  "Determining Whether Instruments Granted in Share-Based
                  Payment Transactions Are Participating Securities," which
                  requires the allocation of net earnings between common
                  shareholders and participating securities holders when
                  computing earnings per share. As a result, net earnings
                  allocated to common shares for the twelve months ended
                  December 31, 2010 and 2009 was $4.613 billion and $5.733
                  billion, respectively.
          
          NOTE: See attached questions and answers section for further
                explanation of Consolidated Statement of Earnings line items.
          n/m = Percent change is not meaningful.
      

      Questions & Answers

      Q1) What drove the strong sales growth in the quarter?

      A1) Worldwide Pharmaceutical sales increased 22.5 percent, including an unfavorable 0.9 percent effect of exchange rates, driven by strong international pharmaceutical sales growth of approximately 30 percent. Sales in the quarter reflected the contribution from the Solvay Pharmaceuticals and Piramal Healthcare Solutions acquisitions, which closed in February 2010 and September 2010, respectively.

      U.S. growth of HUMIRA was 13.2 percent. International operational sales growth for HUMIRA was 17.4 percent, which excludes an unfavorable 4.5 percent effect of exchange rates. Global lipid franchise sales growth was 19 percent, including the international TriCor sales contribution from the Solvay acquisition. U.S. Niaspan sales growth of 12.7 percent exceeded the growth rate of the overall cholesterol market.

      Double-digit growth in Worldwide Vascular sales was driven by international vascular sales growth of approximately 37 percent. Abbott holds the number-one global position in metallic stents, guidewires, as well as drug-eluting stents with XIENCE V and XIENCE PRIME. Globally, Abbott's drug-eluting stent franchise continues to perform well, including strong international performance in Europe and Japan.

      Worldwide Nutritional products sales growth was flat, including a favorable 1.3 percent impact from exchange. Growth in the United States during the quarter was negatively impacted by the infant nutrition recall that was announced in September. Production resumed in October. Inventory is near normal operating levels, and we are recapturing market share.

      Growth in Worldwide Diagnostics was driven by high-single-digit growth in U.S. diagnostics sales, with continued double-digit growth in Abbott's Molecular and Point of Care diagnostics businesses.

      Q2) What drove the strong increase in the fourth-quarter gross margin ratio?

      A2) The gross margin ratio before and after specified items is shown below (dollars in millions):

          
                                                              4Q10
                                                              ----
                                                     Cost of     Gross     Gross
                                                     Products   Margin    Margin
                                                       Sold     ------       %
                                                       ----                 ---
          As reported (GAAP)                           $4,045    $5,923    59.4%
          Adjusted for specified items:
          Restructuring/integration (acquisitions/
           cost reductions)                             ($120)     $120     1.2%
          As adjusted                                  $3,925    $6,043    60.6%
      

      The adjusted gross margin ratio of 60.6 percent increased 230 basis points from the prior year when the adjusted gross margin ratio was 58.3 percent. This increase was driven by strong performance across several businesses, including vascular, pharmaceuticals, diabetes and diagnostics, as well as a favorable impact from foreign exchange rates.

      Q3) What is Abbott doing to further reduce costs and improve profitability?

      A3) In response to changes in the healthcare industry, including U.S. Health Care Reform and the challenging regulatory environment, today Abbott announced a restructuring in its U.S. pharmaceutical business to streamline commercial and manufacturing operations, improve efficiencies and reduce costs.

      Abbott forecasts total specified items associated with this cost reduction initiative over the next several years of approximately $295 million, which includes transfer of product manufacturing to other facilities. These charges include employee-related costs of approximately $135 million, accelerated depreciation of approximately $65 million, and other related exit costs of approximately $95 million mainly related to product transfers. Non-cash charges included in the total will be approximately $65 million, reflecting primarily accelerated depreciation.

      Specified items related to this initiative of approximately $165 million are forecast to occur in 2011, with roughly $140 million projected in the first quarter.

      Q4) What drove SG&A and R&D investment in the quarter?

      A4) In the fourth quarter, both SG&A and R&D investment increased strong double-digits, reflecting Abbott's continued investment in programs to drive future growth, as well as increases associated with the addition of Solvay Pharmaceuticals. Ongoing R&D expense as a percentage of sales was nearly 10 percent, reflecting continued investment in Abbott's broad-based pipeline, including programs in vascular devices, immunology, neuroscience, oncology and HCV.

      Q5) What was the tax rate for the fourth-quarter 2010?

      A5) The ongoing tax rate this quarter was 16.4 percent, in line with Abbott's previous forecast, and reconciled below:

          
                                              4Q10
                                              ----
                                  Pre-Tax   Taxes on    Tax
                                   Income   Earnings    Rate
          As reported              $1,768      $327     18.5%
          Specified items            $653       $69     10.6%
                                     ----       ---     ----
          Excluding specified
           items                   $2,421      $396     16.4%
      

      Q6) How did specified items affect reported results?

      A6) Specified items impacted fourth-quarter results as follows:

          
                                                             4Q10
                                                             ----
          (dollars in millions, except earnings-
           per-share)                                  Earnings
                                                       --------
                                                    Pre-   After-    EPS
                                                    tax      tax     ---
                                                    ---      ---
          As reported (GAAP)                       $1,768  $1,441   $0.92
          Adjusted for specified items:
          Restructuring/integration
           (acquisitions/cost reductions)            $415    $346   $0.23
          Acquired in-process research and
           development                               $238    $238   $0.15
                                                     ----    ----    ----
          As adjusted                              $2,421  $2,025   $1.30
      

      Restructuring/integration (acquisitions/cost reductions) is primarily associated with acquisition closing, restructuring, and integration costs for the Solvay Pharmaceuticals and Piramal Healthcare Solutions acquisitions. This item also includes cost reduction initiatives to improve efficiencies, primarily related to continuing efforts in the vascular and core laboratory diagnostic businesses.

      Acquired in-process research and development is related to the agreement with Reata to develop and commercialize bardoxolone methyl outside the United States, excluding certain Asian markets.

      The impact of specified items by Consolidated Statement of Earnings line item is as follows (dollars in millions):

          
                                                   4Q10
                                                   ----
                                 Cost of     R&D    Acquired   SG&A    Other
                                 Products    ---     IPR&D            (Income)/
                                   Sold              -----             Expense
                                   ----                                -------
          As reported (GAAP)       $4,045  $1,058     $238    $2,797    ($48)
          Adjusted for specified
           items:
          Restructuring/
           integration
           (acquisitions/cost
           reductions)              ($120)   ($81)      --     ($200)   ($14)
          Acquired in-process
           research and
           development                 --      --    ($238)      --       --
                                     ----    ----    -----     ----    -----
          As adjusted              $3,925    $977      --    $2,597     ($62)
      

      Q7) What are the key areas of focus in Abbott's broad-based pipeline?

      A7) Across its businesses, Abbott has more than 350 clinical trials underway and expects to deliver more than 75 new products or indications over the next five years. In 2010, we added a total of four new molecular entities that are in late-stage development, and expect to have nearly 20 new molecular entities and indications in Phase 2 or 3 development by the end of 2011. We also expect numerous new trial starts and new data presentations throughout the year. Following are select highlights from breakthrough research across both pharmaceuticals and medical products pipelines:

          
          - Hepatitis C
             - Abbott's antiviral program is focused on developing treatments for
               hepatitis C (HCV), a disease that affects more than 180 million
               people worldwide, with approximately three to four million people
               newly infected each year. Abbott's broad-based HCV programs include
               its partnership with Enanta Pharmaceuticals to discover protease
               inhibitors, as well as its internal programs focused on additional
               viral targets.
             - Abbott currently has three HCV mechanisms of action in clinical
               trials, including protease polymerase and NS5A inhibitors. Abbott is
               well positioned to explore combinations of these compounds, both
               with and without the current standard of care, a strategy that has
               the potential to markedly transform current treatment practices by
               shortening therapy duration, improving tolerability and increasing
               cure rates.
          - Chronic Kidney Disease
             - Abbott recently entered into an agreement with Reata Pharmaceuticals
               for ex-U.S. rights to bardoxolone, an investigational treatment for
               chronic kidney disease (CKD). Bardoxolone is a first-in-class anti-
               inflammatory that activates Nrf2, a pathway involved in the
               progression of CKD. A Phase 2b study was recently completed and
               initiation of a global Phase 3 trial is targeted to begin in the
               coming months.
          - Women's Health
             - Abbott's collaboration agreement with Neurocrine to develop and
               commercialize elagolix for the treatment of endometriosis-related
               pain and fibroids brings Abbott a novel, first-in-class oral
               gonadotropin-releasing hormone (GnRH) antagonist. A Phase 2 study in
               endometriosis was recently completed.
          - Neuroscience / Pain
             - Abbott is conducting innovative research in neuroscience, where it
               has developed compounds that target receptors in the brain that help
               regulate mood, memory and other neurological functions. Abbott has
               more than a dozen new molecular entities in clinical trials for
               conditions such as schizophrenia, pain, Alzheimer's disease,
               Parkinson's disease and multiple sclerosis (MS). This includes three
               compounds in development for Alzheimer's.
             - Abbott's neuroscience pipeline includes a novel, next-generation
               antibody, daclizumab, which entered Phase 3 development in 2010 for
               relapsing remitting MS (RRMS), the most common form of the disease.
             - Abbott is pursuing compounds that could provide relief across a
               broad spectrum of pain states, such as chronic back pain,
               postoperative pain and cancer pain.
          - Oncology
             - Abbott's oncology pipeline includes therapies that represent
               promising, unique scientific approaches to treating cancer. Abbott
               is focused on the development of targeted treatments that inhibit
               tumor growth and improve response to common cancer therapies. Abbott
               currently has nine new molecular entities in human trials.
             - The oncology pipeline includes: ABT-263, a Bcl-2 family protein
               antagonist; ABT-869, a multi-targeted kinase inhibitor; and ABT-888,
               a PARP-inhibitor that is being studied in a variety of cancers.
               Additionally, Abbott is evaluating a number of promising mechanisms
               in its pre-clinical pipeline, including work on an early-stage cMET
               antibody biologic for cancer.
             - The acquisition of Facet Biotech brought several oncology
               collaborations, including elotuzumab, a late-stage compound in
               development for multiple myeloma. We expect to initiate the Phase 3
               clinical program with our partner company this year.
          - Immunology
             - Abbott's scientific experience with the anti-TNF biologic HUMIRA
               serves as a strong foundation for its continuing research in
               immunology. In its pipeline, Abbott continues to explore additional
               indications for HUMIRA and is working to advance development of its
               early discovery programs, including oral DMARD therapies, as well as
               other potential biologic targets.
             - Additionally, Abbott's proprietary DVD-Ig technology represents an
               innovative approach that can target multiple disease-causing
               antigens with a single biologic agent. This technology could lead to
               combination biologics for complex conditions such as cancer or
               rheumatoid arthritis, where multiple pathways are involved in the
               disease.
          - Molecular Diagnostics
             - Abbott expects to launch more than 12 new molecular diagnostic
               products over the next two to three years, including several novel
               oncology and infectious disease assays, as well as improved
               instrument systems. Abbott received approval from the U.S. Food and
               Drug Administration (FDA) to market the Abbott RealTime HBV assay
               for measuring viral load or the amount of hepatitis B virus in a
               patient's blood, as well as a new sensitive molecular diagnostic
               test and instrument to simultaneously detect two of the nation's
               most prevalent sexually transmitted diseases, gonorrhea and
               chlamydia.
          - Diagnostics
             - In 2010, Abbott launched a number of key assays on its ARCHITECT
               immunochemistry platform, which will significantly broaden its
               industry-leading menu. These tests include assays to assess Chagas
               disease, ovarian cancer and the first HIV combination assay approved
               for use in the United States, which detects the virus days earlier
               than current U.S. tests.
             - Abbott expects to launch several more products this year and is
               researching dozens of novel biomarkers focusing on important areas
               such as diabetes, infectious disease, and neuroscience disorders, as
               well as developing next generation systems.
          - Vascular Devices
             - Abbott has one of the industry's most robust vascular pipelines and
               expects to deliver more than 10 coronary technologies over the next
               five years. Abbott is working on well-staged incremental advances,
               and truly game-changing technologies that have the ability to
               restate the market.
             - ABSORB Bioresorbable Vascular Scaffold (BVS) - Abbott recently
               received CE Mark in Europe for the world's first drug-eluting BVS
               for the treatment of coronary artery disease. ABSORB restores blood
               flow by opening a clogged vessel and providing support to the vessel
               until it dissolves, leaving patients with a treated vessel free of a
               permanent metallic implant. Abbott has the most advanced BVS
               clinical program in the industry.
             - MitraClip - Presented additional data from the pivotal trial,
               EVEREST II, at the TCT conference, which continued to demonstrate
               the safety and sustained meaningful clinical benefits of the therapy
               for the treatment of mitral regurgitation. Abbott's MitraClip system
               is on the market in Europe and is currently under review for
               approval by the FDA.
             - Next-generation DES - Abbott has several next-generation DES
               platforms in development. This includes XIENCE PRIME, our next-
               generation drug-eluting stent (DES) that offers improved
               deliverability, especially in long lesions. XIENCE PRIME is on the
               market in Europe, and is in clinical trials in the United States
               with an expected launch in 2012. XIENCE Nano for small vessels is on
               the market in Europe and under U.S. FDA review. Our ultra thin DES
               is also in development. It's designed to improve clinical outcomes
               by reducing vessel injury upon deployment, enabling faster healing
               and improving deliverability in complex anatomy.
             - Core Coronary products - Abbott is continuing to expand its position
               in the more than $2 billion core coronary market. Abbott launched
               its next-generation balloon dilatation catheter, TREK, in Europe
               last year and expects to launch TREK in the United States and Japan
               in early 2011. In addition, Abbott has a new line of guidewires in
               development.
          - Vision Care
             - Abbott expects 20 new products and technology advancements over the
               next five years, including the launch of a new contact lens solution
               that is underway in Europe and the United States. In its market-
               leading LASIK business, Abbott is expanding its proprietary laser
               platform into new vision correction applications, including cataract
               surgery, and is developing new diagnostic instruments and treatments
               to improve visual outcomes. Abbott also continues to expand its
               premium and standard intraocular lenses (IOL), including Synchrony,
               its next-generation IOL approved in Europe and other countries
               around the world. Synchrony is currently under FDA review in the
               United States.
      

      Modal title

      Also from this source

      Abbott's Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe

      Abbott's Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe

      Abbott, a global healthcare leader, announced today that the Cologuard Plus® test has received CE Mark under the European Union's In Vitro Diagnostic ...

      Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

      Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

      Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose–ketone sensing technology...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Dividends

      Dividends

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.